Search Results
Your search for ,twO matches 12324 pages
Showing 601 - 650When Cancer and Cardiovascular Disease Intersect
The annual Global Cardio-Oncology Summit (GCOS) was held September 22 to 24 in Minneapolis, with 430 health-care professionals attending from 20 countries. The Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology...
Eyeing the Future of Oncology: Highlights From the Presidential Symposium at ESMO Congress 2024
At the European Society for Medical Oncology (ESMO) Congress 2024, the Eyes to the Future Presidential Symposium showcased innovative approaches in personalized medicine, immunotherapy resistance, and artificial intelligence (AI)-driven pathology analysis. These presentations, focusing on the...
Evolving Role of MRD Status in Multiple Myeloma
The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in...
Inotuzumab Ozogamicin With Low-Intensity Chemotherapy in Older Patients With CD22-Positive Philadelphia Chromosome–Negative B-Cell Precursor ALL
In a phase II trial (EWALL-INO) reported in the Journal of Clinical Oncology, Chevallier et al found that inotuzumab ozogamicin combined with low-dose chemotherapy was active in the first-line treatment of older patients with newly diagnosed CD22-positive Philadelphia chromosome–negative B-cell...
Use of Aumolertinib Extends Progression-Free Survival in Stage III EGFR-Mutated NSCLC
Aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, has shown efficacy as maintenance therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to data presented at the International Association for the Study of Lung Cancer...
Addition of Lenvatinib to Ifosfamide/Etoposide in Children and Young Adults With Relapsed Osteosarcoma
In a phase II study (OLIE) reported in JAMA Oncology, Gaspar et al found that the addition of lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival in children or young adults with relapsed or refractory osteosarcoma. Study Details In the global open-label...
Distant Recurrence Risk Among Women With Early Breast Cancer Enrolled in Clinical Trials Between 1990 and 2009: EBCTCG Analysis
In an analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reported in The Lancet, Hills et al found that risk of distant recurrence declined over time among women with early breast cancer enrolled in clinical trials between 1990 and 2009. Study Details The pooled analysis...
New Marker for Immunotherapy Response in Hepatocellular Carcinoma
A newly described stage of lymph node–like structures, known as tertiary lymphoid structures, identified in hepatic tumors following presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a recent study published by Shu et al in Nature...
Scientists Develop a ‘Digital Twin’ Model to Predict Cancer Treatment Responses
Researchers have created a “digital twin” model constructed from the clinical and molecular profiles of patients with cancer that accurately predicted how a patient is likely to respond to a specific chemotherapy. The approach optimizes the treatment choice for patients using available clinical...
Early Results Show Novel Agent Has Clinical Activity in FGFR3-Driven Advanced Bladder Cancer
In a phase I clinical trial (SURF301) investigating the fibroblast growth factor receptor 3 (FGFR3) oral inhibitor TYRA-300 in patients with advanced bladder cancer, the drug showed early antitumor activity and produced lower rates of significant adverse events compared with pan-FGFR inhibitors....
Mutations and DNA Structures May Drive Urothelial Carcinoma
Researchers may have uncovered how urothelial carcinoma originates and progresses, according to a novel study published by Nguyen et al in Nature. The findings provided insights into the biology of urothelial carcinoma and may point to new therapeutic strategies for this difficult-to-treat cancer...
My Melanoma Could Have Been Prevented
I have many of the risk factors for melanoma. I’m fair-skinned, blue-eyed, and have a family history of melanoma, as well as other skin cancers, so I’ve always been diligent about practicing sun safety and maintaining annual full-body skin exams to catch any suspicious moles or lesions that could...
Whole-Person Cancer Care: A Transformative Vision for Oncology
Guest Editor’s Note: Advances in cancer treatments have led to an increase in survival rates, but the quality of life is often diminished during survivorship. Because modifiable personal behavior contributes to health-care outcomes, interventions that support healthy behaviors may improve health...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Raising Awareness of the Health Consequences of Alcohol Consumption During and After a Cancer Diagnosis
In 2023, the World Health Organization (WHO) declared that “no level of alcohol consumption is safe for our health.”1 The warning came decades after the International Agency for Research on Cancer classified alcohol as a Group 1 carcinogen, which is the highest risk group, and also includes...
AMA House of Delegates Adopts ASCO-Sponsored Resolutions on Interpretation of Stark Law and Prior Authorization Costs
On September 23, 2024, the U.S. House of Representatives passed the Seniors’ Access to Critical Medications Act of 2024 (H.R. 5526), which would make permanent a waiver put in place during the COVID-19 pandemic that allowed Medicare patients to receive medications dispensed by in-office pharmacies...
Outcomes With Adjuvant ICI Treatment in Resected Stage III/IV Melanoma
In an analysis of two clinical trials reported in the Journal of Clinical Oncology, Weber et al identified “cure rates” with adjuvant nivolumab, ipilimumab, and placebo in patients with resected stage III/IV melanoma. Study Details The analysis used mixture cure models (MCMs) to estimate cure rates ...
Cosmetic Outcomes With Two Schedules of Partial-Breast Irradiation in Early Breast Cancer
In the Canadian phase II OPAR trial reported in the Journal of Clinical Oncology, Kim et al found no difference in adverse cosmesis with partial breast irradiation (PBI) in five daily fractions of 30 Gy vs 27.5 Gy given over 1 week in patients with early breast cancer. The aim of the trial was to...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Heart Failure and Cancer: New Insights Into Reciprocal Relationship
Investigators have highlighted a critical connection between heart failure and cancer, demonstrating how shared mechanisms may contribute to the incidence and progression of both diseases, according to a recent scientific statement published by Bloom et al in the Journal of Cardiac Failure....
Listening to Music May Accelerate Postsurgical Recovery
Listening to music may accelerate postsurgical recovery, according to recent findings presented by Raees et al at the American College of Surgeons (ACS) Clinical Congress 2024. Background “When patients wake up after surgery, sometimes they feel really scared and don’t know where they are,”...
Patient-Level Data Support Perioperative Use of Nivolumab in Resectable NSCLC
An examination of patient-level data from the phase III CheckMate 816 and CheckMate 77T trials supports the perioperative use of the PD-1 inhibitor nivolumab plus chemotherapy, as compared with the neoadjuvant use of nivolumab plus chemotherapy without adjuvant therapy, in resectable non–small...
New Hope for Patients With HER2-Mutant NSCLC: Durable Responses to Two Novel Targeted Therapies
Two novel oral HER2 tyrosine kinase inhibitors have demonstrated promising efficacy in patients with HER2-mutant non–small cell lung cancer (NSCLC), potentially transforming the treatment landscape for this rare but challenging subset of lung cancer cases. According to data presented at the...
Osimertinib Plus Savolitinib: Responses Reported in First-Line Treatment of MET-Aberrant, EGFR-Mutant NSCLC
The combination of the EGFR tyrosine kinase inhibitor osimertinib and the MET inhibitor savolitinib has demonstrated clinically meaningful improvements compared with osimertinib alone as a first-line treatment of patients with de novo MET-aberrant, EGFR-mutant advanced non–small cell lung cancer...
ACS Program May Reduce Postsurgical Mortality, Improve Care Among Older Patients
Implementing the American College of Surgeons (ACS) Geriatric Surgery Verification program may reduce rates of postsurgical mortality and increase the proportion of patients with documentation standards such as advanced care directives, according to two new studies presented by Horattas et al and...
Cancer Diagnoses May Be Linked to Lasting Financial Challenges
Researchers have found that financial fallout can follow patients with cancer and their families as financial bankruptcy, lower credit scores, and other types of financial challenges in the years following a cancer diagnosis, according to two new studies presented by Gomez-Mayorga et al and...
Regorafenib in Refractory Advanced Gastric Cancer
As reported in the Journal of Clinical Oncology by Pavlakis et al, the phase III INTEGRATE IIa study showed improved overall survival with regorafenib plus best supportive care vs placebo vs best supportive care in patients with refractory advanced gastric/esophagogastric junction cancer. Study...
Three Days Was Enough
My dad agreed to receive hospice on a technicality. It happened after weeks of trying to get him home oxygen. My brother drove him to the oncologist’s office, and I helped him get into the wheelchair. He did not complain, but just asked me to hold his coffee mug, smiling because I snuck him a...
What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults vs Older Adults?
Younger adults with colon cancer tend to be diagnosed at a later stage and have more aggressive types of tumors. Additionally, young patients living with colorectal cancer have long-term, adverse consequences on their lives, which are different from the impact the disease has on older adults,...
STS Launches Two New Thoracic Surgery Risk Calculators
The Society of Thoracic Surgeons (STS) announced the introduction of two new risk calculators to inform physician-patient decision-making in thoracic surgery. Engineered using contemporary data from the STS General Thoracic Surgery Database, the interactive tools may provide surgeons with accurate, ...
New Data From SWOG S1826 Trial May Confirm Benefit of Nivolumab Plus AVD in Patients With Hodgkin Lymphoma
Researchers have found that the combination of nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) may reduce the risk of cancer progression and mortality in patients with Hodgkin lymphoma compared with standard treatment, according to a recent study published by Herrera et al in The New ...
Advancing Diversity, Equity, and Inclusion Through a Challenging Policy Landscape
Among most members of the health-care and oncology workforces, the lofty goals of the organizational framework of diversity, equity, and inclusion (DEI) seem to be clear and indisputable: to promote the fair treatment and full participation of all people, particularly groups who have historically...
Tumor Treating Fields Therapy Receives FDA Approval in Metastatic NSCLC
On October 15, 2024, Novocure announced the U.S. Food and Drug Administration (FDA) approval of Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) who have experienced disease progression on or after...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
Updated Findings in Prostate Cancer Screening With Systemic Biopsy vs MRI-Targeted Biopsy
Updated results of a Swedish screening study (GOTEBORG-2), reported in The New England Journal of Medicine by Hugosson et al, indicate that omitting biopsy among individuals with negative magnetic resonance imaging (MRI) results eliminated a high proportion of diagnoses of clinically insignificant...
New Directions in ALL, CML, and CLL Treatment
The Society of Hematologic Oncology (SOHO) 2024 Annual Meeting showcased several groundbreaking studies in the field of hematologic oncology, including key findings in childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). The ASCO...
Higher Dosage of Radioembolization With Y-90 Therapy May Improve Survival Rates and Facilitate Curative Treatment in Patients With Hepatocellular Carcinoma
Researchers found that a higher dosage of radioembolization treatment using yttrium (Y)-90 microspheres than previously recommended may benefit patients with hepatocellular carcinoma, according to a recent study published by Chen et al in Liver Cancer. The findings could be practice-changing....
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, was bolstered by the positive overall survival analysis...
Sintilimab/Bevacizumab in Relapsed or Persistent Ovarian Clear Cell Carcinoma
In a Chinese phase II trial (INOVA) reported in The Lancet Oncology, Peng et al found that the combination of sintilimab and bevacizumab showed activity in patients with relapsed or persistent ovarian clear cell carcinoma. Study Details In the multicenter trial, 37 evaluable patients with exposure...
Global Disparities May Exist in Availability, Timeliness of New Cancer Drugs
Despite considerable progress in the discovery and development of new cancer drugs between 1990 and 2022, there may be disparities in both the availability and timeliness of these treatment options globally, particularly among lower-income countries, according to a recent study published by Li et...
Two Universities to Develop Incisionless Prostate Cancer Surgery Using MRI and Robotics
Researchers at Case Western Reserve University and Vanderbilt University have received a $3.7 million grant from the National Cancer Institute to pioneer a novel approach to prostate cancer surgery that combines advanced robotics and low-field magnetic resonance imaging (MRI) technology. Overview...
Can Blood Test Predict Survival in Metastatic Prostate Cancer?
A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who...
One-Dose HPV Vaccination Approach May Help to Eliminate Cervical Cancer
Canadian vaccination programs may switch to a one-dose, gender-neutral human papillomavirus (HPV) vaccination approach to eliminate cervical cancer, according to a recent study published by Drolet et al in the Canadian Medical Association Journal. Background HPV is known to cause cervical cancer...
ACA’s Dependent Coverage Expansion May Have Benefited Young Adult Patients Diagnosed With Cancer
Investigators have uncovered that during the Patient Protection and Affordable Care Act’s (ACA) first decade, the survival rates of Dependent Coverage Expansion–eligible young adult patients with cancer may have improved, according to a recent study published by Roth et al in Cancer. The federal...
Coping With the Risk of Hereditary Cancer
Three years ago, it had become clear that I needed to be tested for the BRCA1/2 mutation. I knew my family history of cancer was not good. My paternal grandmother died of breast cancer when she was just 41, and her mother had likely died of cervical cancer when she was in her 50s. More recently,...
Two U.S. Scientists Named Recipients of the 2024 Nobel Prize in Physiology or Medicine
The 2024 Nobel Prize in Physiology or Medicine has been awarded jointly to two U.S. scientists: Victor Ambros, PhD, and Gary Ruvkun, PhD, for the discovery of microRNA and its role in post-transcriptional gene regulation. The recipients were named in a news release issued by The Nobel Assembly at ...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
ChatGPT May Demonstrate Human-Level Assessment of Brain Tumor MRI Reports
In the field of radiology, where a correct diagnosis is critical to ensure proper patient care, large language models such as ChatGPT may improve accuracy or offer a second opinion in assessing brain tumor magnetic response imaging (MRI) reports, according to a recent study published by Mitsuyama...
DESTINY-Breast12: T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least...
‘Encouraging’ Pathologic Responses Achieved With Novel Combination Regimen in Early-Stage NSCLC
In the multiarm phase II NeoCOAST-2 trial, neoadjuvant treatment with datopotamab deruxtecan (Dato-DXd) plus the monoclonal antibody durvalumab and single-agent platinum chemotherapy led to promising rates of pathologic complete and major pathologic responses in patients with early-stage non–small...
